Galera Therapeutics - News Releases

Nov 20, 2020	Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference	View HTML PDF Version
Nov 10, 2020	Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates	View HTML PDF Version
Nov 03, 2020	Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference	View HTML PDF Version
Oct 27, 2020	Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer	View HTML PDF Version
Oct 23, 2020	Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer	View HTML PDF Version
Oct 22, 2020	Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer	View HTML PDF Version
Sep 22, 2020	Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer	View HTML PDF Version
Sep 16, 2020	Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19	View HTML PDF Version
Sep 14, 2020	Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit	View HTML PDF Version
Sep 08, 2020	Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer	View HTML PDF Version